1.77
Schlusskurs vom Vortag:
$1.82
Offen:
$1.88
24-Stunden-Volumen:
392.12K
Relative Volume:
0.24
Marktkapitalisierung:
$4.00M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-6.91M
KGV:
-0.5429
EPS:
-3.26
Netto-Cashflow:
$-6.14M
1W Leistung:
-14.08%
1M Leistung:
-5.35%
6M Leistung:
-37.89%
1J Leistung:
-55.92%
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Firmenname
Galmed Pharmaceuticals Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie GLMD mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
GLMD
Galmed Pharmaceuticals Ltd
|
1.77 | 4.65M | 0 | -6.91M | -6.14M | -3.26 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2020-05-22 | Herabstufung | B. Riley FBR | Buy → Neutral |
2020-02-04 | Eingeleitet | Craig Hallum | Buy |
2020-01-30 | Fortgesetzt | Cantor Fitzgerald | Overweight |
2019-12-02 | Eingeleitet | Canaccord Genuity | Buy |
2018-12-12 | Eingeleitet | B. Riley FBR | Buy |
2018-08-02 | Bestätigt | Maxim Group | Buy |
2018-07-13 | Eingeleitet | Stifel | Buy |
2018-07-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
2018-06-12 | Bestätigt | H.C. Wainwright | Buy |
2018-03-15 | Hochstufung | Maxim Group | Hold → Buy |
2018-02-14 | Herabstufung | Maxim Group | Buy → Hold |
2018-02-12 | Bestätigt | H.C. Wainwright | Buy |
2017-11-15 | Eingeleitet | ROTH Capital | Buy |
2017-08-08 | Bestätigt | H.C. Wainwright | Buy |
2017-07-31 | Bestätigt | Maxim Group | Buy |
2016-08-01 | Bestätigt | Maxim Group | Buy |
2016-07-06 | Fortgesetzt | ROTH Capital | Buy |
2016-03-28 | Fortgesetzt | H.C. Wainwright | Buy |
2015-06-23 | Eingeleitet | H.C. Wainwright | Buy |
2015-05-06 | Eingeleitet | Sun Trust Rbsn Humphrey | Buy |
Alle ansehen
Galmed Pharmaceuticals Ltd Aktie (GLMD) Neueste Nachrichten
Galmed Pharmaceuticals Ltd. Stock Analysis and ForecastRapid portfolio appreciation - jammulinksnews.com
What drives Galmed Pharmaceuticals Ltd. stock priceMassive stock growth - jammulinksnews.com
Is Galmed Pharmaceuticals Ltd. a good long term investmentTurbocharged investment results - jammulinksnews.com
What analysts say about Galmed Pharmaceuticals Ltd. stockMarket-beating performance - jammulinksnews.com
The Role of News and Events in Galmed Pharmaceuticals Ltd Inc. (GLMD) Price Performance - investchronicle.com
Why India’s Pharmaceutical Stocks Are on the Rise High Accuracy Trade SignalsRapid market gains - PrintWeekIndia
Solara Active Pharma Sciences Limited (SOLARAPP)’s Trend in 2025Free Stock Market Forecast Reports - jammulinksnews.com
PLAB Stock Analysis and ForecastSkyrocketing profit margins - jammulinksnews.com
What makes Galmed Pharmaceuticals Ltd. stock price move sharplyFree Insider Trading Tips - Newser
Why Galmed Pharmaceuticals Ltd. stock attracts strong analyst attentionSafe and Scalable Investment Tips - Newser
How Galmed Pharmaceuticals Ltd. stock performs during market volatilitySteady Profit Stock Forecasts - Newser
Galmed Pharmaceuticals Ltd. to Host Earnings Call - ACCESS Newswire
Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond Nash - marketscreener.com
Galmed Pharmaceuticals Unveils Biomarker Signature for Aramchol, Expanding Market Potential - TipRanks
Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH - Longview News-Journal
Wall Street Zen Upgrades Galmed Pharmaceuticals (NASDAQ:GLMD) to Sell - Defense World
Galmed Pharmaceuticals: Q1 Earnings Snapshot - New Haven Register
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Galmed Pharmaceuticals Reports Q1 2025 Financial Results and Advances in Oncology - TipRanks
Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - PR Newswire
Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated at StockNews.com - Defense World
Galmed Pharmaceuticals Unveils Promising Aramchol Results in PSC Models - TipRanks
Galmed (GLMD) Announces Promising Pre-Clinical Results for Aramc - GuruFocus
Galmed (GLMD) Announces Promising Pre-Clinical Results for Aramchol in Treating PSC | GLMD Stock News - GuruFocus
Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models - PR Newswire
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
Galmed Pharmaceuticals Ltd’s Market Journey: Closing Weak at 1.29, Down -11.64 - DWinneX
Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by Analysts at StockNews.com - Defense World
Galmed Pharma Shares Jump 10% On Cancer Drug Data: Retail Traders Turn ‘Extremely Bullish’ By Stocktwits - Investing.com India
GLMD Advances Cancer Treatment with Promising Aramchol Results | GLMD Stock News - GuruFocus
Finanzdaten der Galmed Pharmaceuticals Ltd-Aktie (GLMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):